Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (GLMD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
glmd · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Galmed Pharmaceuticals Ltd. (GLMD) measures how much investors pay for each dollar of the company's trailing earnings. GLMD's current PE ratio of N/A is calculated by dividing its stock price of $0.47 by its TTM earnings per share of -$1.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Galmed Pharmaceuticals Ltd.You GLMD | $3M | N/A | — | -$1.57 |
 Biodexa Pharmaceuticals Plc BDRX | $1M | N/A | — | -$113.82 |
 BioVie Inc. BIVI | $13M | N/A | — | -$11.87 |
 Chemomab Therapeutics Ltd. CMMB | $11M | N/A | — | -$1.41 |
 PMGC Holdings Inc. ELAB | $3M | N/A | — | -$378.74 |
 InMed Pharmaceuticals Inc. INM | $3M | N/A | — | -$8.36 |
 iSpecimen Inc. ISPC | $0M | N/A | — | -$91.15 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.39 | — | |
2024-12-31 FY2024 | — | $-8.08 | — | |
2023-12-31 FY2023 | — | $-30.05 | — | |
2022-12-31 FY2022 | — | $-10.66 | — | |
2021-12-31 FY2021 | — | $-19.80 | — | |
2020-12-31 FY2020 | — | $-20.28 | — | |
2019-12-31 FY2019 | — | $-14.54 | — | |
2018-12-31 FY2018 | — | $-8.15 | — | |
2017-12-31 FY2017 | — | $-14.77 | — | |
2016-12-31 FY2016 | — | $-22.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Galmed Pharmaceuticals Ltd. (GLMD) measures how much investors pay for each dollar of the company's trailing earnings. GLMD's current PE ratio of N/A is calculated by dividing its stock price of $0.47 by its TTM earnings per share of -$1.57.
Frequently asked questions
GLMD pe ratio · 6 questionsGLMD's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.47 and TTM EPS of -$1.57. Data sourced from Financial Modeling Prep via GLMD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Galmed Pharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08